(Q35549863)

8 August 2017

An update on the changing indications for androgen deprivation therapy for prostate cancer (English)

1 reference

8 August 2017

Kristene Myklak

1

1 reference

PubMed ID

22110986

8 August 2017

Shandra Wilson

series ordinal

2

1 reference

8 August 2017

7 February 2011

1 reference

8 August 2017

1 reference

8 August 2017

2011

1 reference

8 August 2017

419174

1 reference

Creative Commons Attribution 3.0 Unported

8 August 2017

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Castration-refractory prostate cancer: New drugs in the pipeline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Quality of life three years after diagnosis of localised prostate cancer: population based cohort study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Screening and prostate-cancer mortality in a randomized European study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Mortality results from a randomized prostate-cancer screening trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Definitive radiotherapy for prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Cognitive effects of hormone therapy in men with prostate cancer: a review

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Survival following primary androgen deprivation therapy among men with localized prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

New treatment approaches for prostate cancer based on peptide analogues

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Androgen deprivation therapy for prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Physiologic basis for hormonal theapy in carcinoma of the prostate

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits tumor necrosis factor alpha and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta

27 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Changes in body composition during androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Insulin sensitivity during combined androgen blockade for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Cumulative cost pattern comparison of prostate cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Quality of life after radical prostatectomy or watchful waiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Management of the side effects of androgen deprivation therapy in men with prostate cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216006

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

24 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F419174

Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer

21 January 2018

1 reference

12 December 2020

Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level

1 reference

12 December 2020

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

12 December 2020

Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study

1 reference

12 December 2020

EAU guidelines on prostate cancer

1 reference

12 December 2020

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy

1 reference

12 December 2020

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy

1 reference

12 December 2020

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

1 reference

12 December 2020

Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)

1 reference

12 December 2020

Is hormone therapy a protective factor for late hematuria after high-dose radiotherapy in prostate cancer?

1 reference

12 December 2020

Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance

1 reference

12 December 2020

Intermittent androgen deprivation therapy: redefining the standard of care?

1 reference

12 December 2020

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/419174

1 reference

8 August 2017

1 reference

8 August 2017

1 reference

PubMed ID

22110986